Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Innovation Associate for highly specific Tumour Associated Carbohydrate Antigens

Project description

Novel therapeutic targets against colorectal cancer

Immune system activation constitutes a promising approach for the treatment of cancer. However, it has not been possible to identify cancer-specific targets for therapeutic and diagnostic purposes. The EU-funded InnoTACA project aims to identify tumour-associated carbohydrate antigens (TACA) in colorectal cancer (CRC), which currently has limited treatment options. Researchers envision the identification of molecules that will serve as leads for the development of safer and more cost-effective immunotherapies applicable to even advanced unresectable CRC. Moreover, these targets can be used to predict the clinical outcome during cancer management and treatment.

Objective

CellmAbs is a recent but fast growing biopharmaceutical spinoff dedicated to the development of immuno-oncology agents that target only cancer cells, promoting the activation of the immune system and inhibiting growth of cancer in both early and late stages.
In spite of many advances in diagnostic and treatment development, many cancers still have no targeted therapy or have limited or toxic treatment options. Early detection is crucial to optimize treatment and substantially reduce incidence and mortality. In spite of the advent of new and improved genomic and proteomic technologies, it has not been possible to identify cancer-specific therapeutic targets or molecules that are able to reliably and accurately predict outcomes during cancer management and treatment. Cancers such as colorectal cancer (CRC) have very poor standard of care and thus own an unmet need for reliable and specific targets. The discovery of tumour associate carbohydrate antigens (TACA) is very promising but is still very insipient due to lack of experts, knowledge and technology on the field.
InnoTACA will address several unmet needs by presenting the grounds for hiring an Innovation Associate with relevant expertise and experience on groundbreaking technology to innovate TACA discovery to apply in cancer theranostic, combining high-quality transferable-skill training with excellent scientific training in glycomics. InnoTACA addresses the CellmAbs need of identifying highly specific TACAs, which would serve as a lead for the development of safer and more cost-effective immunotherapies, even for advanced unresectable CRC.
The InnoTACA Associate and such immunotherapies will provide CellmAbs with improved products to capitalize and compete with current healthcare business and it will allow CellmAbs to connect with other high-tech SMEs focused in pharmaceutical and medical development, and partners with strong translational clinical and research backgrounds.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Coordinator

CELLMABS SA
Net EU contribution
€ 100 075,00
Address
POLO TECNOLOGICO OBIDOS RUA DA CRIATIVIDADE
2510-216 Leiria
Portugal

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Continente Centro (PT) Oeste
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data